http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-114835759-A
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_048f16c527f4c5abde2048c4436c331b |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07F15-0093 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-55 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-555 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07F15-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-55 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00 |
| filingDate | 2022-05-16-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_e82e6fa5ad9c7f6edb2a15df9758f2d2 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_8e9b9a531f82f58371552898e5696029 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_7b043d24ce3bba7741106f0d337cc0e4 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_f68f70d8e370ca5cb1f6278ff4d0c5ce |
| publicationDate | 2022-08-02-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | CN-114835759-A |
| titleOfInvention | Melatonin-platinum (IV)-carbon-nitrogen long-chain complex, preparation method and application thereof in tumor medicine |
| abstract | The invention discloses a melatonin-platinum (IV)-carbon-nitrogen long-chain complex, a preparation method and its application in tumor medicine; melatonin is introduced on the side of the axial site of a Pt (IV) coordination center Compared with the unmodified platinum drug, the drug in this system has better tumor killing ability, and the cytotoxicity is improved by dozens of tens of tens of tens of tens of compared with cisplatin. In particular, the killing effect on sex hormone-related tumors, such as ovarian cancer, cervical cancer, and breast cancer cells, is more obvious; at the same time, in addition to the potential anti-tumor effect of melatonin, it reduces cisplatin resistance, which is comparable to melatonin- Compared with platinum (IV) complex, its sustained release effect is better. Compared with traditional bivalent platinum and similar tetravalent platinum drugs, the drug has the advantages of good curative effect and less side effects, and provides a new method for the modification of tetravalent platinum. ideas. |
| priorityDate | 2021-05-21-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 70.